ARS Pharmaceuticals (SPRY) Cash & Current Investments (2020 - 2026)

ARS Pharmaceuticals has reported Cash & Current Investments for 7 years, with the latest figure at $201.0 million in Q1 2026.

• Quarterly Cash & Current Investments fell 27.11% year-over-year to $201.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $201.0 million (down 27.11% YoY) and the FY2025 annual result came in at $245.0 million, down 21.98% from the prior year.
• Cash & Current Investments declined to $201.0 million in Q1 2026 per SPRY's latest filing, from $245.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $314.0 million in Q4 2024 and troughed at $201.0 million in Q1 2026.
• A 5-year average of $250.1 million and a median of $252.2 million in 2023 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 356.82% in 2022, down 32.16% in 2022.
• Over 5 years, Cash & Current Investments stood at $274.4 million in 2022, then declined by 16.77% to $228.4 million in 2023, then jumped by 37.51% to $314.0 million in 2024, then slipped by 21.98% to $245.0 million in 2025, then decreased by 17.97% to $201.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $201.0 million, $245.0 million, and $288.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.